RAPP
Rapport Therapeutics, Inc.
Key Financials
Operating Income
$-125099000
↓ 50.6%
Net Income
$-111483000
↓ 42.4%
Revenue
$20.0M
N/A
EPS (Diluted)
$-2.86
↑ 24.3%
Total Assets
$512.4M
↑ 62.7%
Shareholders' Equity
$484.7M
↑ 58.7%
Total Liabilities
$27.8M
↑ 192.2%
Cash & Equivalents
$52.6M
↓ 7.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/8/2026 | View on SEC |
| 144 | 10/6/2026 | View on SEC |
| 4 | 10/1/2026 | View on SEC |
| 144 | 9/30/2026 | View on SEC |
| 4 | 9/24/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 8/26/2026 | View on SEC |
| 4 | 8/26/2026 | View on SEC |
| 144 | 8/25/2026 | View on SEC |
| 144 | 8/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RAPP |
| Company Name | Rapport Therapeutics, Inc. |
| CIK | 2012593 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-321-8020 |